Jiangsu Hengrui Medicine Co., Ltd. (HKG:1276)

Market Cap	375.35B
Revenue (ttm)	31.30B
Net Income (ttm)	7.34B
Shares Out	n/a
EPS (ttm)	1.17
PE Ratio	51.17
Forward PE	43.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,269,329
Average Volume	3,799,774
Open	57.90
Previous Close	56.90
Day's Range	56.30 - 58.50
52-Week Range	52.50 - 59.90
Beta	n/a
RSI	52.06
Earnings Date	Aug 22, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial numbers in CNY